Published in Cancer Weekly, February 8th, 2005
"The use of many common clinically relevant chemotherapeutics is often limited due to insufficient delivery to the tumor and dose-limiting systemic toxicities," scientists in Denmark explained. "Therefore, therapeutics that specifically target tumor cells and are nontoxic to normal cells are required."
To help provide such agents, S.S. Jensen and colleagues working at LiPlasome Pharma A/S developed "a novel class of liposomes composed of lipid prodrugs, which use the increased secretory phospholipase A2 type IIA (sPLA2 )...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.